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ABSTRACT 
 
THE EFFECTS OF OVARIAN HORMONES AND EXERCISE ON GENE MARKERS 
OF CARDIAC DYSFUNCTION 
 
MAY 2015 
 
ANISHA S. PATEL, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Prof. Sarah Witkowski 
 
 Heart disease is the leading cause of death in women in the United States. 
Premenopausal women appear to have better cardiac function and lower risk of heart 
disease compared to male postmenopausal female counterparts. Ovarian hormone loss 
influences blood pressure homeostasis and causes systemic inflammation, which may 
result in chronic stress on the heart. Two key physiological changes in cardiac 
dysfunction are reemergence of the fetal gene pattern and myocardial remodeling. 
Physical activity has been linked to improved cardiac function. The purpose of this study 
was to investigate the effects of ovariectomy on early markers of cardiac dysfunction and 
fibrosis and to determine if voluntary physical activity alters expression patterns in 
ovariectomized mice. We investigated the effects of ovariectomy and exercise on cardiac 
expression of fetal genes and markers and mediators of fibrosis in two cohorts of 8-10 
week old female mice. Ovariectomized mice had greater expression of cardiac fetal genes 
and real time-PCR (RT-PCR) results indicated activation of the fibrosis pathway. 
Exercise was able to influence the expression of some markers of cardiac dysfunction. 
We concluded that ovarian hormone loss and associated physiological changes such as 
iv 
 
increased adiposity and systemic inflammation trigger early changes in cardiac gene 
expression that precede overt cardiac dysfunction.    
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CHAPTER 1 
INTRODUCTION 
Heart disease is the leading cause of death in women. Prior to menopause, women 
tend to have better cardiac outcomes compared to men, exhibiting preserved contractility 
with age and better responses to cardiac stressors such as hypertension and myocardial 
injury (19, 66). After menopause, mortality rates from heart disease increase and 
prognosis worsens. Most women who suffer from heart failure are postmenopausal and 
more women over the age of 45 who have a heart attack die within 1 year compared with 
men (29, 82). 
The gender disparity associated with heart disease combined with the detrimental 
effects of menopause on female cardiac health provides evidence of a possible 
cardioprotective role of ovarian hormones. Ovarian hormone loss is linked to increased 
adiposity, insulin resistance, and systemic inflammation (85). Estrogen-mediated 
regulation of the renin-angiotensin-aldosterone system (RAAS) is lost after menopause, 
resulting in RAAS hyperactivity and consequential problems with natriuresis and diuresis 
(15, 34). Resulting blood pressure imbalance and increased hemodynamic load induce 
bouts of ischemia and increase wall stretch on the heart. This disease environment closely 
resembles the in utero environment of the growing fetal heart and is characterized by the 
re-expression of a fetal gene pattern (84, 106). While this regression in gene transcription 
has been well documented in models of acute cardiac injury or induced heart disease, 
early changes in expression patterns of cardiac dysfunction markers in a model of ovarian 
hormone loss have not yet been established (15, 84, 94).  
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In heart disease models, activation of the fetal gene pattern can exacerbate RAAS 
activity, resulting in increased levels of intracardiac angiotensin II (AngII) (23, 87). 
Acute injury or chronic stress can initiate an inflammatory response, cardiomyocyte 
hypertrophy, and myocardial remodeling (10). The myocardium is comprised of a variety 
of resident cells and AngII can trigger cardiac fibrosis through activation of cardiac 
fibroblasts (CFB) (48, 58). Activated cardiac fibroblasts differentiate to myofibroblasts 
(MFBs), cells that produce collagen and other ECM proteins, resulting in increased 
fibrosis (24).   
Estrogen supplementation has been shown to reduce negative remodeling of 
myocardial tissue, indicating the hormone may have anti-fibrotic effects (70). Both 
cardiac myocytes and fibroblasts express functional estrogen receptors and 17β-estradiol 
has been shown to inhibit collagen synthesis in cardiac fibroblasts by downregulation of 
AngII receptors (32, 125).  To date, severe cardiac fibrosis and tissue remodeling has 
been shown in models inducing acute injury or stress or have investigated the effects of 
estrogen related to disease pathology in an aged model or induced cardiac dysfunction; 
signs of cardiac tissue fibrosis at early stages of ovarian hormone loss without intentional 
ischemia or cardiac injury have not been established.  
Physical activity has been shown to decrease the risk for heart disease. Exercise is 
linked to reduced cardiac dysfunction and attenuation for pathological remodeling (51). 
Recent studies have also shown exercise may decrease cardiac fibrosis attributed to low 
estrogen levels (70). Preliminary data from our lab has shown that physical activity 
influences a possible inflammatory and fibrotic response to low ovarian hormone levels 
in the heart. Understanding potential benefits of exercise on cardiac function in an 
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ovariectomy model may provide alternatives to hormone therapy, a controversial 
treatment for postmenopausal women. 
The specific aims and hypotheses for this study have been outlined below: 
 
Aim 1: To study the effects of ovariectomy on the markers of disease in mouse heart 
tissue.  
Hypothesis 1: The hearts of ovariectomized (OVX) mice will exhibit evidence of 
dysfunction via a fetal gene expression pattern compared with sham surgery 
(SHAM) hearts. 
Aim 2: To study the effects of ovariectomy on gene expression patterns that indicate 
fibrosis in mouse heart tissue. 
Hypothesis 2: OVX mice will express more cardiac profibrotic markers and will 
exhibit more extracellular matrix (ECM) protein deposition compared with 
SHAM counterparts. 
Aim 3: To determine whether exposure to voluntary wheel running physical activity 
(EX) influences markers of cardiac dysfunction and fibrosis associated with ovariectomy. 
Hypothesis 3A: EX mice will exhibit lower expression of cardiac fetal gene 
markers compared with sedentary (SED) counterparts. 
Hypothesis 3B: EX mice will exhibit lower cardiac ECM gene expression 
compared with SED counterparts. 
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CHAPTER 2  
LITERATURE REVIEW 
2.1 Introduction 
 This literature review will highlight the prevalence of heart disease in women and 
the importance of studying the increase in risk that is associated with menopause. 
Changes in ovarian hormone levels will be assessed as key risk factors; and the 
relationship between ovariectomy, the cardiac fetal gene program, and fibrosis will be 
detailed. Lastly, the influence of exercise on heart disease pathology and dysfunction will 
also be explored. 
2.2 Heart Disease & Women  
2.2.1 Prevalence and Pathology 
 Heart disease is currently the leading cause of death in women. In 2010, Direct 
and indirect costs associated with heart disease exceeded $300 billion (29). According to 
CDC data from 2009, one in four female deaths was caused by heart disease in the United 
States (56). This statistic increased to 1 in 3 female deaths by 2013 and will likely 
augment with the increasing prevalence of factors associated with heart disease such as 
hypertension, diabetes, obesity, and high cholesterol (73, 74). The increase in the aging 
population is also a significant risk factor as individuals over the age of 65 have a greater 
risk of stroke, myocardial infarction, coronary heart disease (CHD), hypertension, and 
heart failure (37).  
Sex differences have been shown in a variety of heart and heart disease-related 
outcomes.  While women preserve myocyte number and size with age, male myocardial 
mass decreases as a result of a reduction in the number of myocytes, and this loss of mass 
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leads to compensatory myocyte hypertrophy (78). This pathological hypertrophy results 
in decreased systolic function and increased left ventricle diameter over time (31). 
Chamber dilation and wall thinning result in poor cardiac contractility in males, while 
contractility is better preserved in females with age (14, 19). Premenopausal women fare 
better in response to hypertension, aortic stenosis, hypertrophic cardiomyopathy, and 
acute myocardial ischemia compared to their male counterparts (66, 82). Premenopausal 
women also appear to have better diastolic function than men, although diastolic function 
decreases in both sexes with age (31, 78). Gender disparities regarding heart health and 
function indicate that females have cardioprotection prior to menopause, potentially from 
ovarian hormones. 
The contribution of ovarian hormones to cardiac pathology, function, and 
outcomes is evident when comparing pre- and postmenopausal women. Most women that 
suffer from heart failure are postmenopausal (82). After menopause, female mortality 
rates due to heart disease increase significantly and surpass those of men (Figure 1) (28, 
97). Given the increases in the elderly population, women past menopause will have a 
direct impact on the prevalence of heart disease and heart disease associated costs. After 
65, the incidence of heart failure nears 10 per 1000 people and American Heart 
Association projections show that by 2030, the prevalence of heart failure will increase 
by 25% (29). The prevalence of CVD, hypertension and heart failure increases drastically 
in women and surpasses prevalence in male counterparts with age (Figure 2) (17). The 
increase in risk associated with menopause combined with the dramatic increases in size 
of the elderly population pose a significant problem regarding the health burden and 
treatment costs in the United States.  
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The reduction in circulating ovarian hormones that accompanies menopause is 
linked to an increased risk for heart disease, indicating that ovarian hormones may be 
cardioprotective (66). The direct effects of ovarian hormone reduction on heart health 
Figure 2: Prevalence of cardiovascular disease (CVD) in adults ≥ 20 years of age (NHANES 
2007-2010). Source National Heart, Lung, and Blood Institute {{355 Anonymous 2012}}.  
 
Figure 1: CVD mortality trends for males and females (United States:1979-2010) {{354 
Go,A.S. 2014}}.  
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have not been thoroughly assessed although some literature suggests that cardioprotective 
effects of the ovarian hormone estrogen (E2) include decreased cardiac inflammation and 
pathological remodeling (55). For example, ovariectomization in mice, a model used to 
study postmenopausal physiology, results in greater left ventricular hypertrophy in 
response to pressure overload compared with ovariectomized mice supplemented with 
17β-estradiol, indicating that E2 may be involved in pathways regulating pathological 
hypertrophy (110).  
To date, most investigations have initiated heart disease pathology through drastic 
interventions such as trans aortic constriction, ischemia, or other interventions that induce 
rapid hypertension and cardiac hypertrophy (24, 49, 122). These methods, while 
effective, accelerate heart failure and do not provide data on subtle changes in cardiac 
health and signaling that result solely from reduced ovarian hormones. 
2.2.2  Ovarian Hormones 
The two main hormones secreted by the ovaries are estradiol/estrogen and 
progesterone. Minor concentrations of E2 are also secreted by adipose tissue, skin, 
muscle and endometrial tissue. Carrier proteins bind to and transport about 99% of 
circulating E2s while the unbound 1% is considered physiologically active. E2s are 
steroid hormones that act on E2 receptors (ERs). Membrane E2 receptor activation can 
trigger signaling pathways in the cell or result in a conformational change in the protein 
that initiates downstream events in the nucleus via transcription factor activation or 
inhibition (26, 77). Additionally, E2 can induce genomic effects by binding to receptors 
in the cell nucleus (77). The two main ERs, ER-α and ER-β, act via the nongenomic 
pathway when activated by E2. These receptors exhibit different actions in the 
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cardiovascular system. In general, ER-α prevents vascular smooth muscle cell 
proliferation while ER-β regulates pathologic cardiac hypertrophy (54). Both receptor 
types are found in cardiac myocytes. An animal study showed that ovariectomized mice, 
aged mice, and aged ovariectomized mice had similar densities of ERs compared to sham 
surgery mice (104). Thus, prevalence of ER-α and ER-β do not appear to be influenced 
by not ovariectomy or aging.  
Progesterone is another steroid hormone secreted by the ovaries and is well 
known for its function in pregnancy to prepare the endometrial lining for the fetus; 
however limited research has been conducted on the cardiovascular effects of 
progesterone independently of E2 (18). Progesterone binds to two main receptors, PR-A 
and PR-B, affecting gene expression and protein phosphorylation. Like E2, progesterone 
is also able to initiate signaling cascades or influence gene activity via cell membrane or 
nucleic PRs (26). Both of these receptors are found in cardiac tissue, indicating 
progesterone has potential influence on cardiac function; however evidence is equivocal 
regarding their effect. High serum levels of progesterone in men and women are 
associated with increased risk for congestive heart failure and in vivo animal studies have 
found progesterone causes inotropic dysfunction, or problems with contractility, although 
other studies have shown no effect of progesterone on contraction (76, 116).  
While progesterone and E2 combination therapy is related to increased risk for 
non-cardiovascular events in women with prior heart disease, these hormones in 
combination appear to reduce risk for heart disease and benefit cardiac function in 
healthy postmenopausal women (40). A longitudinal study conducted on healthy 
postmenopausal women observed the effects of hormone replacement therapy (HRT) 
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with E2-only supplementation, E2 and progesterone in combination, and placebo. E2 
alone or in combination with progesterone improved lipoprotein and reduced fibrinogen 
levels (116). Another study found that postmenopausal women with 4 months of 
combined hormone replacement therapy exhibited improved indicators of cardiac systolic 
and diastolic function including cardiac output, stroke volume, ejection fraction, and end 
diastolic volume (98). 
The influence of HRT on coronary heart disease risk was investigated by the 
Heart and estrogen/progestin Replacement Study (HERS), the first large randomized, 
double-blind placebo controlled study to examine this relationship; Hulley et al., found 
that hormone replacement therapy was not cardioprotective as placebo and HRT 
participants developed similar numbers of heart problems over 4 years between 
controlled clinical time points. Additionally, more HRT participants experienced 
coronary events during the first year of the study compared to placebo group (41). A 
study by the Women’s Health Initiative aimed to determine if HRT could prevent CHD 
and participants were to be followed over an 8-year period. After 5 years the study was 
halted as a disproportionate number of participants on HRT began to develop breast 
cancer. Data analysis at this point found a significant association (p=0.05) between HRT 
and CHD, stroke, breast cancer, and pulmonary embolism (16, 88). Due to the 
uncertainty regarding the influence of HRT on cardiac health and the high risks 
associated with HRT, other methods of treatment like exercise should be investigated.  
2.3 Evaluating Cardiac Pathology: The Fetal Gene Program  
 In order to understand the increased risk for heart disease in postmenopausal 
women, the effects of ovarian hormone loss on the heart tissue must be studied. Initial 
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signs of menopause-induced stress in the heart tissue that precede outward cardiac 
dysfunction, such as poor contractility or hypertrophy, have not been established. The 
fetal gene program is a pattern of mRNA expression that is indicative of cardiac 
dysfunction in adults. An adult heart experiences bouts of ischemia, increasing 
hemodynamic load, and hypertrophy in a disease state, much like a fetal heart in utero. In 
response to chronic stress or acute injury, the adult heart begins to revert expression of 
cardiac genes associated with stretch and hypoxia from the healthy archetype to a disease 
pattern that resembles fetal expression (84). 
In utero, the fetal heart exhibits gene expression patterns and a metabolic system 
that differ from the post natal, healthy adult heart. In the low oxygen environment of the 
uterus, the heart metabolizes carbohydrates such as glucose and lactate (25). After the 
stress of birth and a 24-hour exposure to an environment rich in oxygen, the post natal 
heart begins to shift the metabolic paradigm and relies primarily on fatty acid oxidation 
for energy (64). The fetal heart also experiences growth-induced stretch characterized by 
upregulation of cardiac hormones responding to stretch like atrial natriuretic peptide 
(ANP) and beta natriuretic peptide (BNP) (42, 84). Compared to fetal expression, these 
stretch-related hormones are downregulated in the healthy adult heart (44, 107). Under 
postnatal physiological conditions, atrial cardiomyocites express ANP while BNP mRNA 
is found in both atrial and ventricular tissue (12, 65, 123). These hormones function to 
reduce blood pressure by regulating natriuresis and diuresis, and inhibiting activation of 
the renin-angiotensin-aldosterone system (RAAS) (3, 75).  
Apart from stretch hormone activation, gradual increases in hemodynamic load 
are also accompanied by a transition in cardiac muscle fiber expression. Initially, the pre-
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natal heart expresses the sarcomeric protein α-skeletal actin whereas the adult heart 
primarily expresses α-cardiac actin (93). Both isoforms are structurally similar, differing 
in only 4 four protein residues; however the transition from skeletal to cardiac actin is a 
characteristic difference between the fetal and adult heart (43). The murine fetal heart is 
also characterized by expression of β-myosin heavy chain (β-MHC) and this contractile 
element transitions to the α isoform (α-MHC) after birth. Humans, however, express β-
MHC in cardiac tissue throughout fetal development as well as adulthood (91, 92). 
Additionally, the growing fetal heart slowly develops its inotropic pattern, gradually 
increasing expression of Calcium ATPase (SERCA-2a), a calcium handling protein. 
SERCA-2a allows for muscle relaxation by enabling the re-uptake of calcium into the 
sarcoplasmic reticulum after contraction. After birth, the established levels of SERCA-2a 
are maintained throughout adulthood (8, 84).  
 In a disease state, the adult heart is exposed to stressors that resemble the stimuli 
of the in utero environment. Bouts of ischemia induce periods of hypoxia and the heart 
experiences stretch in response to increased hemodynamic load. The heart reacts to these 
disease-related changes by reverting to a fetal heart pattern of metabolism (5, 84, 107). 
The failing adult heart has glycogen stores comparable to the fetal heart indicating that 
disease may activate a switch to a metabolic pattern that relies on glucose as a substrate 
(11). Chronic stress and the increased hemodynamic load exacerbates myocardial wall 
strain resulting in the upregulation of stretch hormones ANP and BNP; overall levels of 
BNP mRNA increase and ventricles are recruited to synthesize ANP (42, 90). Greater 
levels of cardiac ANP and BNP also function systemically to hormonally regulate RAAS 
activation in the kidneys and prevent increases in blood pressure (15).  
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As disease induced hypertrophy progresses, the heart reverts back to increased 
expression of α-skeletal actin and downregulation of the formerly predominant cardiac 
isoform (5, 42, 107). Expression of α-MHC is also downregulated in response to heart 
disease, while β-MHC levels are preserved, resulting in an isoform shift that resembles 
the fetal expression pattern in rodents. While human adult hearts only express β-MHC, 
these levels decrease with disease (84, 91, 92).  Cardiac stress also affects calcium 
handling in the heart tissue, in models of induced pressure overload or severe hypoxia, 
SERCA-2a expression is reduced or diminished entirely (42, 84, 107). McMullen et al. 
used a mouse model of pathological pressure overload to characterize the expression 
pattern of fetal genes. The Northern blot in Figure 2 shows the difference in cardiac 
mRNA expression between an aortic banding model of pressure overload (BAND) and 
rats that underwent a sham surgery (SHAM). The BAND group, exhibited a pathological 
response to the pressure overload with greater expression of ANP, BNP, β-MHC, and α-
ska, resembling the expression pattern established in developing fetal hearts (5, 71).  
  
 
 
Figure 3: Ventricle RNA expression of fetal genes in pressure overload model 
(Band) exhibited an increase in markers responding to mechanical stretch and a 
decrease in contractile function markers compared to control (Sham) {{358 
McMullen,J.R. 2003; 180 Bernardo,Bianca C. 2010}}.  
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2.4 Fibrosis 
 In response to chronic stress or acute injury, the myocardium begins to remodel. 
Increased peripheral resistance forces the heart tissue to stretch and as this pathological 
hypertrophy occurs, the distance between adjacent myocytes and other resident cells 
increases. The heart tissue compensates for this growth with fibrotic remodeling as cells 
increase secretion of ECM fibers and the matrix thickens. This process of malignant 
fibrosis is a combined effort of a variety of cardiac cell types. 
Cardiac fibroblast (CFBs) cells make up 27% of the murine heart and 40%-60% 
of the adult human heart (96, 100). Forming a three-dimensional structure around cardiac 
myocytes, fibroblasts serve to maintain structural integrity of the heart tissue. More 
importantly, CFBs regulate extracellular matrix homeostasis by controlling ECM protein 
turnover rate (120). Acute injury or chronic stress conditions induce a fibroblast signaling 
response that serves to heal the injury or compensate for the increased load. In a stressed 
environment, often caused by increased peripheral resistance or systemic inflammation, 
cardiac fibroblasts differentiate into a new cell type with properties that resemble a 
combination of fibroblasts, smooth muscle cells, and vascular pericytes (10, 36). This cell 
type, known as the myofibroblast (MFB), is associated with pathology. Current research 
hypothesizes that in a disease state, quiescent (or inactive) CFBs along with other 
resident precursor cells, also differentiate into MFBs (10).  
Initially the CFB becomes a proto-myofibroblast (proto-MFB), which is 
characterized by increased cytoplasmic actin stress fiber production and the formation of 
a dense matrix of collagen and fibronectin fibers (10, 108). Stage two of myofibroblast 
formation occurs as the protein transforming growth factor beta-1 (TGFβ-1) binds to its 
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receptor, acting on a kinase enzyme to phosphorylate SMAD proteins (SMAD 2 and 3). 
These proteins form a complex and translocate to the nucleus of the proto-MFB in order 
to activate transcription of genes coding for profibrotic proteins. MFBs increase the 
production of fibronectin and collagen (I and III) and begin to produce and secrete the 
ECM protein vimentin, resulting in a denser, fiber rich matrix (81, 120). During this 
differentiation process, MFBs also begin to express endothelin-1 (ET-1) which 
participates in a positive feedback loop to promote MFB formation. ET-1 also stimulates 
the production of α–SMA (α-smooth muscle actin), a key indicator that the cell has 
reached the second stage of MFB formation (22, 81).  
Acute injury and chronic stress are hypothesized to induce this MFB formation 
through different pathways. Acute injury, such as a myocardial infarct, initiates a wound 
healing response in the heart that promotes cardiac fibrosis. White blood cells and 
macrophages infiltrate the infarct area and initiate an inflammatory response. Secretion of 
TGFβ-1 by the pro-inflammatory cells phosphorylates SMAD proteins in fibroblasts, 
resulting in MFB formation, migration, and ECM protein deposition (4, 68). TGFβ-1 can 
also act through non-canonical mechanisms via the JNK and p38 kinase pathways (9, 58, 
59). Chronic stress, like the systemic inflammation that accompanies increased 
postmenopausal adiposity, is characterized by the prevalence of pro-inflammatory 
cytokines in the blood and perturbations to blood pressure homeostasis. This stress is 
hypothesized to induce MFB formation in the heart via the renin-angiotensin system (10).  
In a healthy heart the local natriuretic peptide system shares an inverse 
relationship with the systemic RAAS although this balance is lost in disease. In a healthy 
individual, the kidneys respond to low sodium levels, low blood volume and blood 
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pressure by releasing renin, a protease that leads to angiotensin II production, increased 
sodium and fluid retention and vasoconstriction to regain pressure homeostasis.  On the 
other hand, with increased blood pressure and cardiac stretch, ANP and BNP are released 
and induce vasorelaxation, natriuresis and diuresis.  In addition, ANP suppresses renin 
secretion producing an overall effect of reducing blood pressure and pressure on the 
myocardium (15, 95). On the other hand, in many pathological circumstances, increases 
in plasma levels of renin is accompanied by ANP and BNP upregulation in cardiac tissue 
in an attempt to prevent RAAS hyperactivity (15). In vitro research has also shown that 
ANP acts to protect the heart from pathological remodeling in that it inhibits TFGβ-
induced SMAD signaling and prevents MFB transformation in response to pressure-
overload (62). Li et al. also found that ANP-null mice exhibited increased alpha-smooth 
muscle actin expression and colocalization with collagen deposits, indicating that low 
levels of natriuretic peptides are associated with greater pathological CFB differentiation, 
increased cardiac hypertrophy and pathological remodeling (62). Therefore, the 
activation of ANP occurs in an attempt to protect the heart from pressure overload and 
negative remodeling. 
Recent studies have found that apart from the systemic role in RAAS, angiotensin 
II plays a direct role in hypertrophy and remodeling of the heart. Systemic renin 
accumulation in the heart increases intracardiac angiotensin II formation. High levels of 
cardiac angiotensin II exacerbate diastolic dysfunction, myocyte hypertrophy, and tissue 
fibrosis (39). Cardiac angiotensin II (AngII) is an upstream inducer of TGFβ-1 signaling 
in fibrosis (6, 7, 35, 58). In response to higher levels of local AngII, fibroblasts increase 
TGFβ-1 synthesis, promoting CFB differentiation to an MFB phenotype (7, 9, 10).  
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Myofibroblast proliferation and increased extracellular matrix fiber deposition 
causes pathological structural changes in the heart. As a result, heart contractile function 
is altered. Excess protein deposition in the ECM increases the distance between adjacent 
cardiac muscle cells which hinders proper contractility and increases wall stiffness (24, 
124). Recent in vitro studies show that myofibroblasts exhibit increased intercellular 
signaling after differentiation, which may be a compensatory mechanism for the 
pathological effects of myocardial remodeling (124). Ovarian hormones such as E2 act 
directly on fibroblast differentiation pathways in response to cardiac hypertrophy.  Mouse 
model studies show that ovariectomized mice, develop greater left ventricular 
hypertrophy as a response to pressure overload compared to ovariectomized mice 
supplemented with 17β-estradiol, indicating that E2 may be involved in pathways 
regulating hypertrophy (110). Both cardiac myocytes and fibroblasts express functional 
E2 receptors and 17β-estradiol has been shown to inhibit collagen synthesis in cardiac 
fibroblasts by downregulation of AngII receptors (32, 125). In response to 
ischemia/reperfusion, E2 improves cardiac recovery by downregulating inflammatory 
factors like tumor necrosis factor alpha (TNF-α) (122). Just as E2 supplementation allows 
for a better response to cardiac injury, E2 loss associated with menopause could have 
detrimental effects on heart health. Investigating the mechanisms underlying cardiac 
fibrosis may provide insight to the effects of menopause on female cardiac function. 
As pathological cardiac fibrosis progresses, myocardial structure regulation is 
affected. Fibroblast proliferation and hyperactivity alters transcription of matrix 
metalloproteinases (MMP) and their tissue inhibitors (TIMPS), which normally maintain 
ECM homeostasis (48, 109). MMP activation has mostly been established as a response 
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to acute injury or in models of acutely induced cardiac hypertrophy (102, 103).  MMP 
activity is also regulated by inflammatory biomarkers AngII and ET-1 (109). In vitro 
experiments of male and female Wistar rat cardiac fibroblasts observed the effects of E2 
supplementation as well as E2 receptor (ER) antagonists on MMP-2 expression. 17β-
estradiol supplementation inhibited MMP-2 expression via activation of E2 receptor α 
(ERα). The study found that activated ERα acts via the ERK 1/2 pathway to 
phosphorylate Elk-1, which downregulates MMP-2 gene transcription (67). The influence 
of E2 on fibroblast expression of MMPs and overall activity suggests a mechanism linked 
to sex-related differences in cardiac fibrosis (67). However, the involvement of MMP 
activation at initial stages of disease is unclear. 
2.5 Inflammation  
Inflammation can be systemic or localized to specific tissues.  Menopause is 
related to increases in systemic inflammatory factors such as monocyte chemotactic 
protein-1 (MCP-1), interleukin 1 beta (IL-1β), IL-10, and TNFα (60, 113). Systemic 
inflammation after menopause may be in part a result of increased adiposity.  Higher fat 
deposition and insulin resistance are associated with the reduction in circulating ovarian 
hormones that occurs after menopause (45). Ovariectomy in mice leads to significant 
increases in body weight and fat mass. Interestingly, studies measuring food intake found 
that ovariectomized mice did not consume more food than control (sham surgery) mice 
(45, 86). In one of these studies, despite similar food intake, the ovariectomized mice 
exhibited increased insulin resistance and gained 25% more weight than control mice 
after 8 weeks. This increase in mass was accompanied by increased hepatic fat 
deposition. Both visceral adipose tissue and lipid droplets in the liver exhibited increased 
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expression of pro-inflammatory markers and white blood cell infiltration the 
ovariectomized mice (86). Therefore, adipose tissue inflammation caused by ovarian 
hormone reduction results in a systemic reaction, initiating an inflammatory response in 
other tissues. A recent study reported that although ovariectomized mice became fatter at 
12 weeks compared with control mice, by 20 weeks the groups were similar weight but 
ovariectomized mice had more adipose tissue inflammation.  By week 26, 
ovariectomized mice had more insulin-resistance compared with controls (111). These 
studies demonstrate that ovarian hormone reduction expedites weight gain and fatty 
deposition initially; although with time ovariectomy does not result in more weight gain 
or fat deposition compared to control mice. The decrease in circulating ovarian hormones 
associated with the loss of the ovaries appears to upregulate adipose-related inflammatory 
markers and may result in an inflammatory response throughout the system. 
Inflammation caused by risk factors for heart disease can also have direct 
influences on cell death and tissue damage in the myocardium. Cardiac tissue responds to 
low-grade stress with oxidative bursts, triggering the production of reactive oxygen 
species (ROS) by local neutrophils as well as mitochondria and various oxidase enzymes 
in the myocardium (69).  Oxidative stress response causes platelet activation, endothelial 
swelling, and neutrophil infiltration, disrupting blood flow and resulting in dysfunction of 
cardiac endothelium (69, 112). This leads to reduced levels of nitric oxide, a common 
vasodilator, and increased production of proinflammatory cytokines and adhesion 
molecules (69).  
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2.6 Physical Activity 
Physical activity has been shown to improve cardiac function and reduce the risk 
for heart disease. Exercise has been linked to reduced systemic inflammation, 
inflammatory biomarkers, and circulating white blood cells (13, 47). A recent study 
showed that exercise decreased negative remodeling in the hearts of spontaneously 
hypertensive rats (70). Therefore, it is possible that physical activity may be able to 
attenuate for the profibrotic outcomes associated with E2 loss and chronic inflammation. 
Exercise may have a direct effect on the heart or may act indirectly by reducing systemic 
inflammation. 
Physical activity is also associated with physiological cardiac hypertrophy, though 
this increase in heart mass is generally benign (5, 114). Resistance training and endurance 
exercise induce concentric and eccentric myocyte hypertrophy, respectively, through a 
pathway regulated by insulin-like growth factor 1 (IGF-1) (72, 114). Unlike pathological 
remodeling, this physiological hypertrophy results in normal or enhanced cardiac 
function that is exhibited by proportional chamber enlargement and improved 
contractility (5). Additionally, physiological hypertrophy does not cause apoptosis or 
alter gene expression of pro-inflammatory/profibrotic markers such as AngII and ET-1 
(5, 114). In a study comparing pathological and physiological cardiac hypertrophy, Kemi 
et al. found that 8-week old female mice, when aerobically trained (wheel running) for 6 
weeks, exhibited cardiac myocytes that were approximately 20% longer and 30% wider 
than those of the sedentary group. Furthermore, the trained group exhibited cardiac 
hypertrophy via activation of the mTOR kinase pathway, with no increases in expression 
of fetal genes ANP, BNP, and skeletal muscle actin. The disease model, created using 
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transverse aortic constriction, also resulted in cardiac hypertrophy; however this 
remodeling was accompanied by increased mRNA expression of ANP, BNP, and skeletal 
muscle actin, indicating a pathological response (51). McMullen et al. also investigated 
the physiological expression pattern of fetal genes in swim-trained rats. Figure 3 shows 
difference between the pathological expression pattern (Band) and the physiological 
expression pattern (Exercise) of the fetal gene program. Both Band and Exercise groups 
exhibited cardiac hypertrophy although the hypertrophy in the Band group was 
accompanied by hypertension and cardiac dysfunction while the exercise group exhibited 
decreased resting heart rate and increased stroke volume, indicating enhanced cardiac 
function (5, 71).   
 
Exercise-mediated hypertrophy is also reversible and does not involve myocardial 
remodeling, while hypertrophy associated with heart disease is irreversible and results in 
WBC infiltration, ECM protein deposition, fibrosis, and eventual heart failure (114). 
These principal differences between physiological and pathological hypertrophy 
Figure 4: Ventricle RNA expression of fetal genes in physiological 
hypertrophy model (Exercise) exhibited a diminished expression of 
markers responding to mechanical stretch and an expression pattern of 
contractile function markers similar to control (Sedentary) {{180 
Bernardo,Bianca C. 2010; 358 McMullen,J.R. 2003}}.  
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distinguish disease-mediated mechanisms and exercise-induced changes in myocardial 
structure.  
Physical activity may 
influence key inflammatory 
markers in an ovariectomy model. 
In a preliminary study from our 
lab, hearts from female C57/BL6 
mice were analyzed for gene 
expression of inflammatory 
markers.  Mice were divided into 
four groups: OVX, OVX+EX, SHAM 
and SHAM+EX. Both OVX and OVX+EX mice underwent a bilateral ovariectomy. For 
8 weeks, these groups were housed in cages and the +EX mice were provided voluntary 
exercise on a running wheel. 
Preliminary data showed 
exercise-exposed mice exhibited 
significantly lower cardiac gene 
expression of IL1-α, a pro-
inflammatory marker, compared 
to OVX (Figure 4).   IL1-α is 
secreted by activated 
macrophages, neutrophils, and 
endothelial cells and causes the proliferation of fibroblasts. 
Figure 5: Interleukin-1α cardiac gene expression. * 
Significantly different from ovariectomized (OVX) female 
mice. 
Figure 6: Plasminogen activator inhibitor-1 (PAI-1) cardiac 
gene expression. * Significantly different from sham surgery 
(SHAM) female mice, + Significantly different from 
ovariectomized (OVX) female mice. 
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The cardioprotective effects of exercise may play a role in other inflammatory 
marker levels. Plasminogen activator inhibitor-1 (PAI-1) functions to prevent 
fibrinolysis, or the degradation of blood clots, and is associated with CVD development 
(30). Plasma levels of PAI-1 have been shown to be significantly decreased after short-
term aerobic training in postmenopausal women (46). In addition to an exercise effect on 
IL1-α levels in our preliminary study, mice exposed to physical activity had lower PAI-1 
cardiac gene expression compared to their sedentary counterparts (Figure 5). More 
research must be conducted in order to see the effects of exercise on inflammation and 
cardiac fibrosis. 
2.7 Overview 
Common risk factors associated with heart disease induce RAAS activation and 
myocyte hypertrophy during the initial stages of pathological remodeling of the heart. 
RAAS activation and chronic cardiac stress may effect fetal gene expression patterns in 
the heart. Over time, the heart is unable to compensate for continuous overload and 
fibrotic pathways are activated. Ovarian hormones interact with multiple factors involved 
in the RAAS system as well as pathological remodeling pathways in the heart. The 
eventual increase in ECM protein deposition and fibrosis that result from this remodeling 
cause decreased contractility and cardiac dysfunction, which results in heart failure.  
The following study evaluates pathways implicated in heart disease pathology as 
they relate to menopause. The murine ovariectomy model is used to illustrate the 
proposed pathways of heart disease related to ovarian hormone loss in postmenopausal 
women.  Further, it is used to evaluate the effectiveness of countermeasures, such as 
physical activity to reduce the negative consequences of ovarian hormone loss on the 
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cardiovascular system. In this study, the mice received surgery at 8-10 weeks of age 
(young adult) and were sacrificed 8 weeks post-surgery therefore this study evaluates the 
early effects of menopause without the added effects of aging. Due to the early time 
period investigated, we chose to use gene expression analyses as gene expression is a 
sensitive technique that can identify early markers of dysfunction prior to translation and 
protein expression.  Classic markers of cardiac dysfunction, the fetal gene program, were 
evaluated in addition to markers of RAAS activation and fibrosis. Importantly, this study 
aimed to evaluate the effects of ovarian hormone loss without induction of hypertension 
or acute pathological stress on the cardiovascular system.  Therefore, our results will be 
relevant to the independent effects of ovarian hormones on heart disease. 
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CHAPTER 3 
METHODS 
3.1 Introduction 
The primary aims of this study are to investigate the effects of ovariectomy and 
exercise on cardiac dysfunction in mice. This chapter will outline the methodologies 
planned to achieve these aims. 
3.2 Animals 
 Mouse models exhibit similar responses to surgical procedures as humans (61, 
66). Bilateral ovariectomy is the most common intervention in animals to simulate 
physiology related to ovarian hormone loss (50). In mice, ovariectomy has been shown to 
reduce circulating estradiol by 67% and does not cause hyperphagia, eliminating the 
effect of overweight and obesity due to consumption (99, 115). Ovariectomy leads to loss 
of all ovarian-derived hormones and therefore precludes analysis of the effects of any one 
hormone; therefore, this model may be more representative of changes that occur with 
menopause. As we propose to study early markers of cardiac dysfunction we will use two 
cohorts of 8 week old (early adult) mice and investigate the effect of exercise at this 
stage.  
3.2.1 Cohort 1: 
Hearts from twenty female C57/BL6 (Harlan) mice were obtained from a study 
conducted at the University of Maryland (118). At 8-10 weeks of age, mice were divided 
into two groups: a sham surgery group (SHAM; n=10) and a bilaterally ovariectomized 
group (OVX; n=10). The mice in the SHAM group were anesthetized but the ovaries 
were left intact. All mice were given ad libitum access to water and standard rodent chow 
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(Purina Laboratory Rodent Diet 5001:23% protein, 4.5%fat, 6% fiber) and were housed 
in a temperature controlled room on a 12h light/dark cycle for eight weeks after surgery.  
Food was removed from all groups 24 hours before mice were sacrificed and weighed. 
Hearts and other tissues were harvested, snap frozen in liquid nitrogen, and stored at -
80˚C until processing. 
3.2.2 Cohort 2: 
Hearts were obtained from a study conducted at the University of Maryland (45).  
Similar to cohort 1, twenty 8-week old C57/BL6 (Harlan) cohort 2 mice were divided 
into two groups: a sham operated group (SHAM) and a bilaterally ovariectomized group 
(OVX). All mice were housed in cages for eight weeks and half of each group (n=5) was 
provided a running wheel for voluntary exercise (EX). Exercise animals were 
individually housed to measure each animal’s activity.  Wheel revolutions were recorded 
by a computer attached to a photocell on each wheel. Data was populated through 
customized software (Lafayette Instruments, Lafayette, IN). The other half of the two 
groups were housed in a standard cage with no wheel and were considered the sedentary 
(SED).  
All mice were given ad libitum access to water and standard rodent chow (Purina 
Laboratory Rodent Diet 5001:23% protein, 4.5%fat, 6% fiber) and were housed in a 
temperature controlled room on a 12h light/dark cycle.  Mice were removed from the 
wheel cages 24 hours prior to sacrifice and food was removed from all groups at this time 
as well. All mice were then sacrificed, weighed, and tissues were harvested, snap frozen 
in liquid nitrogen, and stored at -80°C until processing.  The study was approved by the 
University of Maryland institutional Animal Care & Use Committee (IACUC). 
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3.3 Tissue Analysis 
3.3.1  Gene expression 
RNA was isolated from the heart tissue using the Trizol method (63). Briefly, 50-
100mg of tissue was homogenized in 1ml Trizol and incubated at room temperature for 5 
minutes.  Then, 0.2ml chloroform was added to each sample, mixed, and incubated for 2-
3 minutes.  Samples were centrifuged to separate the aqueous from solid phases. The 
aqueous phase was removed and RNA was precipitated through the addition 0.5ml of 
isopropanol.  Samples were incubated then centrifuged.  The resultant RNA was washed 
with a 75% ethanol solution then dried.  RNA was then rehydrated and stored at -80°C.  
RNA content was determined via spectrophotometry (NanoDrop).   
To synthesize complementary DNA (cDNA), 0.2-1 μg of total RNA (depending 
on the target gene) was reverse transcribed and the reaction was inactivated by incubation 
at 70ºC for 15 minutes. Primers were designed for each target (Table 1) and optimized for 
annealing temperature, dilution, and greater than 95% efficiency. Dissociation melt 
curves were analyzed to determine the specificity of the PCR products. cDNA produced 
from the reverse transcription reaction was mixed with SsoFast EvaGreen (BioRad), and 
forward and reverse primers for each rtPCR reaction (Table 1). PCR was employed using 
GAPDH as a reference for each reaction. GAPDH was evaluated as a reference gene by 
statistical analysis of mean threshold (C(t)) values for each sample. For cohort 1, the 
average C(t) values for each SHAM sample across all genes were compared with those 
for each OVX sample using a two-tailed T-test (p=0.05). For cohort 2, intergroup 
differences between the average C(t) values across all genes were determined with a two-
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way ANOVA. There was a significant effect of group and condition (p=0.013, 0.001), but 
no significant group by condition interactions. 
Quantification of gene expression in each treatment group was analyzed 
according to the 2^∆CT method where the ∆CT = GAPDH CT - target gene CT.  Data 
was expressed normalized to the SHAM SED condition, which was set to 1.   
3.3.2 Statistical Analysis 
 Data is expressed as means ± standard error. Both cohorts were tested for 
normality and equal variance. Differences between groups in cohort 1 were determined 
using two-tailed T-tests with Microsoft Excel. Due to limited sample size, cohort 2 did 
not pass assumption tests. Cohort 2 served as a preliminary analysis, and SigmaPlot 
Software was used to conduct an Analysis of Variance (ANOVA) to determine the effect 
of group (OVX, SHAM) and the effect of condition (SED, EX). Significant interactions 
were analyzed using Tukey’s post hoc testing. Significance was set at an alpha level of p 
< 0.05. 
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Table 1: Gene Expression Targets 
Primer Function   Primer Sequence (5’-3’) 
GAPDH Reference Gene  F: CTCATGACCACAGTCCATGC 
R: CACATTGGGGGTAGGAACAC 
Atrial 
Natriuretic 
Peptide (ANP) 
Fetal Gene Program & 
Cardiac Dysfunction 
Marker 
F: TGCCGGTAGAAGATGAGGTC 
R: AGCCCTCAGTTTGCTTTTCA 
B-type 
Natriuretic 
Peptide (BNP) 
Fetal Gene Program & 
Cardiac Dysfunction 
Marker 
F: CTGAAGGTGCTGTCCCAGAT 
R: CCTTGGTCCTTCAAGAGCTG 
α-Myosin 
Heavy Chain 
(α-MHC) 
Fetal Gene Program & 
Cardiac Dysfunction 
Marker 
F: CTGGGCAAATCCAACAACTT 
R: TCTTGCCTCCTTTGCCTTTA 
β-Myosin 
Heavy Chain 
(β-MHC) 
Fetal Gene Program & 
Cardiac Dysfunction 
Marker 
F: TGCAGCAGTTCTTCAACCAC 
R: TCGAGGCTTCTGGAAGTTGT 
α-Skeletal 
Actin (α-sk ) 
Fetal Gene Program & 
Cardiac Dysfunction 
Marker 
F: CGATATCCGCAAAGACCTGT 
R: GCTGGAAGGTGGACAGAGAG 
Ca2+ ATPase 
(SERCA2a) 
Fetal Gene Program & 
Cardiac Dysfunction 
Marker 
F: CTGTGGAGACCCTTGGTTGT 
R: CAGAGCACAGATGGTGGCTA 
Angiotensin II 
(AngII) 
Induces TGFβ secretion F: AGCAGCCGTCCTTTTGATAA 
R: TGCTGGACACCTTTTTAGGG 
Endothelin-1 
(ET-1) 
Induces TGFβ secretion 
and Stimulates CFB 
Differentiation to MFB 
F: GTGTCTACTTCTGCCACCTGGAC
AT 
R: GGGCTCGCACTATATAAGGGATG
AC 
Transforming 
Growth 
Factor β1 
(TGFβ-1) 
Stimulates CFB 
Differentiation to MFB 
F: ATACGCCTGAGTGGCTGTCT 
R: GGTTCATGTCATGGATGGTG 
α-Smooth 
Muscle Actin 
(α-sma) 
Marker of MFB 
formation 
F: ACTGGGACGACATGGAAAAG 
R: AGAGGCATAGAGGGACAGCA 
Collagen 1 
(Col1) 
ECM Fiber Involved in 
Myocardial Remodeling 
F: TGACTGGAAGAGCGGAGAGT 
R: ATCCATCGGTCATGCTCTCT 
Collagen 3 
(Col3) 
ECM Fiber Involved in 
Myocardial Remodeling 
F: GTCCACGAGGTGACAAAGGT 
R: GATGCCCACTTGTTCCATCT 
Vimentin 
(Vim) 
ECM Fiber Involved in 
Myocardial Remodeling 
F: AAGGAAGAGATGGCTCGTCA 
R: TTGAGTGGGTGTCAACCAGA 
Fibronectin 
(FN) 
ECM Fiber Involved in 
Myocardial Remodeling 
F: CAAGACCATACCTGCCGAAT 
R: CAACTGGTTGGCATGAAATG 
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CHAPTER 4 
RESULTS 
4.1 Cohort 1 
4.1.1 Animal Characteristics 
 Cohort 1 heart weight and body weight information was provided by the 
University of Maryland where the animals were sacrificed (117).  The OVX group had 
significantly greater body weight and significantly lower heart weight to body weight 
ratio compared to SHAM (p<0.001; 0.001, respectively). There was no difference in heart 
weight between groups (Table 2). 
Table 2: Animal Characteristics for Cohort 1 
 HW (g) SEM BW (g) SEM HW/BW SEM 
SHAM 
(n=10) 
0.1295 0.003 22.18 0.270 0.0058 0.0001 
OVX 
(n=10) 
0.1250 0.004 25.33* 0.484 0.0049* 0.0001 
 
 
  
4.1.2  Gene Expression 
Gene expression data for cohort 1 is depicted in fold change relative to the SHAM 
group (set to 1.0) and the genes investigated have been grouped by function for clarity. 
The first group of genes is the signature fetal gene program: ANP, BNP, α-MHC, β-
MHC, α-ska, and SERCA-2a. The second group of genes, angiotensin II, TGFβ-1, 
endothelin-1, and α-sma are implicated in MFB activation and pathological fibrosis in the 
heart. ECM fibers collagen 1 & 3, vimentin, and fibronectin comprise the third group and 
are indicators of myocardial remodeling and fibrosis. 
 
* indicates significant difference from sham surgery (SHAM) female mice (p<0.005). 
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4.1.3 Cohort 1: Fetal Genes 
Cohort 1 expression of many of the fetal genes resembled the expression pattern 
of the pathological model of heart disease (See Figure 3). ANP and BNP, cardiac 
hormones that respond to stretch, showed greater expression (3.43-fold, p=0.063 and 
2.52-fold, p=0.026, respectively) in the OVX group. Expression of contractile filaments 
α-MHC and β-MHC was significantly lower in OVX (0.79-fold, p=0.048 and 0.64-fold, 
p=0.007, respectively) compared to SHAM. The skeletal muscle component α-ska 
showed 1.62-fold greater gene expression in the OVX group (p=0.007) while the calcium 
handling protein Serca-2a showed a 0.735-fold downregulation compared to SHAM 
(p=0.444)(Figure 5). 
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Figure 7: Expression of fetal genes (Cohort 1) Atrial Natriuretic Peptide (ANP), B-type 
Natriuretic Peptide (BNP), α-Myosin Heavy Chain (α-MHC), β-Myosin Heavy Chain (β-
MHC), α-Skeletal Actin (α-ska), and Calcium ATPase (SERCA 2a) depicted as fold change of 
ovariectomized (OVX) female mice (n=10) compared to sham surgery (SHAM) female mice 
(n=10). * indicates that OVX expression was significantly different from SHAM (p<0.05). 
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4.1.4 Cohort 1: Fibrotic Markers 
Mediators of pathological fibrosis showed greater expression in ovariectomized 
mice compared to the sham group. Angiotensin II was 5.28-fold higher in OVX 
(p=0.021) and expression of TGFβ-1 in OVX was 2.97-fold greater than SHAM 
expression (p = 0.017). Expression of endothelin-1, a mediator of fibrosis involved in 
stimulating MFB formation, was 1.7-fold greater in OVX, but this was not statistically 
significant (p=0.255). The MFB marker α-sma mRNA levels were 1.89-fold higher in 
OVX compared to SHAM (p=0.057) (Figure 6). 
 
 
 
 
 
4.1.5 Cohort 1: ECM fibers 
Expression of extracellular matrix fibers was higher in OVX mice compared with 
SHAM, although not statistically significant. Collagen 1 and collagen 3 showed 2.16- and 
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Figure 8: Gene expression of fibrotic markers (Cohort 1) Angiotensin II (AngII), Endothelin-1 (ET-
1), Transforming Growth Factor β1 (Tgfβ1), and α-Smooth Muscle Actin (α-sma) depicted as fold 
change of ovariectomized (OVX) female mice (n=10) compared to sham surgery (SHAM) female 
mice (n=10). * indicates that OVX expression was significantly different from SHAM (p<0.05). 
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2.47-fold higher expression in OVX compared to SHAM (p=0.099; 0.065, respectively). 
OVX also exhibited 2.16-fold greater expression of vimentin and fibronectin was 
upregulated 3.23-fold compared to SHAM (p=0.99; 0.062, respectively) (Figure 7).  
 
 
 
 
4.2 Cohort 2 
4.2.1  Animal Characteristics 
Body weight, heart weight, and food consumption data for cohort 2 animals was 
provided by the University of Maryland, where the animals were sacrificed (45, 117). 
There was no effect of ovariectomy or exercise on heart weight between groups. 
Ovariectomy had a significant effect on body weight and food consumption (p=0.039 and 
p=0.027, respectively). Exercise had a significant effect on food consumption as well 
(p=0.037). Running data was not acquired on this cohort.  Data that was collected 
previously on a similar cohort of animals reveals reduced running distance in OVX 
compared with SHAM (Appendix A) (118). 
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Figure 9: Gene expression of ECM fibers (Cohort 1) Collagen 1 (Col1), Collagen 3 (Col3), 
Vimentin (Vim), and Fibronectin (FN) depicted as fold change of ovariectomized (OVX) 
female mice (n=10) compared to sham surgery (SHAM) female mice (n=10).  
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Table 3: Animal Characteristics for Cohort 2 
 
 HW (g) BW (g) HW/BW Average Food 
Consumption (g) 
SHAM 
SED 
(n=5) 
0.1380 24.19 0.0057 4.943 
OVX SED 
(n=5) 
0.1282 26.73 0.0048 4.229 
SHAM EX 
(n=5)† 
0.1492 24.15 0.0062 5.189 
OVX EX 
(n=5)† 
0.1555 25.81 0.0060 4.912 
 
 
 
4.2.2 Gene Expression 
Gene expression for cohort 2 is depicted in fold change relative to the SHAM 
group (set to 1.0). The gene targets have been grouped by function for clarity with the 
first group consisting of the signature fetal gene program: ANP, BNP, α-MHC, β-MHC, 
α-ska, and SERCA-2a. The second group consists of angiotensin II, TGFβ-1, endothelin-
1, and α-sma; genes implicated in MFB activation and pathological fibrosis in the heart. 
ECM fibers collagen 1 & 3, vimentin, and fibronectin comprise the third group and are 
associated with cardiac remodeling and fibrosis. 
 
4.2.3 Cohort 2: Fetal Genes 
 Expression levels are depicted in fold change relative to the sham sedentary group 
(set to 1.0) and the genes have been organized in the same grouping as that of cohort 1. 
Cohort 2 fetal gene expression showed the influence of exercise on ovariectomized mice. 
There was no effect of ovariectomy or exercise on cardiac gene expression of ANP and 
There were no significant interactions between group and condition. †Note: This data 
represents the full cohort. A sample from both SHAM EX and OVX EX groups was lost 
during shipping and is not included in the gene expression data below.  
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BNP. Both group and condition had significant effects on cardiac mRNA expression of 
myosin isoform α-MHC (p=0.008, 0.001) as well as a significant group by condition 
interaction (p=0.008). α-MHC expression was significantly upregulated in OVX SED and 
SHAM EX compared to sham sedentary (2.07-fold, p=0.001 and 2.34-fold, p=0.001, 
respectively). There was a significant group effect (p=0.006) and group by condition 
interaction (p=0.001) on gene expression of β-MHC. OVX SED and SHAM EX had 
greater mRNA expression of β-MHC compared to SHAM SED (2.11-fold, p=0.001 and 
1.49-fold, p=0.039, respectively). OVX EX expression of β-MHC was significantly lower 
than OVX SED (1.37-fold, p=0.04). Gene expression of skeletal muscle isoform α-ska 
showed a significant overall effect of exercise (p=0.013). There was a significant effect 
of group and condition on gene expression of contractile protein SERCA 2a (p=0.001, 
0.001).  
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4.2.4 Cohort 2: Fibrotic Markers 
There was a significant effect of ovariectomy and exercise on gene expression of 
Angiotensin II, a mediator of cardiac fibrosis (p=0.016, 0.015). Angiotensin II expression 
also had a group by condition interaction and OVX EX hearts had significantly greater 
expression of AngII compared to OVX SED and SHAM EX (4.15-fold, p=0.001, 0.001).   
Gene expression of endothelin-1, another fibrotic mediator, showed a significant effect of 
ovariectomy (p=0.043). TGFβ-1, involved in cardiac growth and remodeling, and α-sma, 
a marker of MFB formation, both showed no significant effects of group or condition 
(Figure 10).  
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Figure 10: Expression of fetal genes (Cohort 2) Atrial Natriuretic Peptide (ANP), B-type Natriuretic 
Peptide (BNP), α-Myosin Heavy Chain (α-MHC), β-Myosin Heavy Chain (β-MHC), α-Skeletal Actin 
(α-ska), and Calcium ATPase (SERCA 2a) depicted as fold change of ovariectomized sedentary (OVX 
SED) female mice (n=5), ovariectomized exercise (OVX EX) female mice (n=4), and sham surgery 
exercise (SHAM EX) female mice (n=4) compared to sham surgery sedentary (SHAM SED) female 
mice (n=10). * indicates fold change was significantly different from SHAM SED, θ indicates 
significant difference from OVX SED, and  indicates significant difference from SHAM EX (p<0.05). 
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4.2.5 Cohort 2: ECM fibers  
ECM fibers, indicators of cardiac fibrosis and tissue remodeling, followed a 
relatively consistent pattern of expression. Collagen 3 gene expression had a significant 
overall effect of exercise (p=0.048). There was no effect of group or condition on cardiac 
gene expression of collagen 1, vimentin, or fibronectin (Figure 12). 
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Figure 11: Gene expression of fibrotic markers (Cohort 2) Angiotensin II (AngII), Endothelin-1 (ET-
1), Transforming Growth Factor β1 (Tgfβ1), and α-Smooth Muscle Actin (α-sma) depicted as fold 
change of ovariectomized sedentary (OVX SED) female mice (n=5), ovariectomized exercise (OVX 
EX) female mice (n=4), and sham surgery exercise (SHAM EX) female mice (n=4) compared to 
sham surgery sedentary (SHAM SED) female mice (n=10). * indicates fold change was significantly 
different from SHAM SED, θ indicates significant difference from OVX SED, and  indicates 
significant difference from SHAM EX (p<0.05). 
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Figure 12: Gene expression of ECM fibers (Cohort 2) Collagen 1 (Col1), Collagen 3 (Col3), 
Vimentin (Vim), and Fibronectin (FN) depicted as fold change of ovariectomized (OVX) female 
mice (n=10) compared to sham surgery (SHAM) female mice (n=10).  
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CHAPTER 5  
DISCUSSION 
Ovarian hormone loss after menopause is associated with an increased risk for 
heart disease and coronary events. In this study, we were interested in cardiac gene 
expression patterns at early stages of ovarian hormone loss in a postmenopausal animal 
model. We also explored exercise as a possible modality for attenuating ovariectomy 
induced changes in cardiac expression. We hypothesized that ovariectomy would cause a 
pathological cardiac gene expression pattern and fibrosis and that voluntary wheel 
running would be related to lower expression markers of dysfunction. Our major findings 
were 1) compared to sham surgery mice, ovariectomized mice expressed a disease 
phenotype of the cardiac fetal gene program, 2) ovariectomized mice upregulated cardiac 
expression of ECM genes and other genes associated with fibrosis, which may be related 
to increased angiotensin II expression and 3) exercise reduced the expression of many 
fibrosis-associated genes. 
5.1 Ovariectomy Causes Activation of the Fetal Gene Program 
Adult re-expression of the fetal gene program in cardiac tissue is a well-
characterized key indicator of heart disease (79, 84, 107). Acute injury or chronic 
systemic stressors produce an environment of hypoxia and increased hemodynamic load 
resulting in compensatory cell hypertrophy in the heart. These pathological changes 
mimic the low oxygen environment and growth-induced wall strain of the fetal heart, 
resulting in the reemergence of fetal expression signature in the diseased heart (84, 107). 
Activation of the fetal gene program has been characterized in various heart disease 
models, including hypertension, myocardial infarction, and heart failure, but it is 
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unknown whether the expression pattern is an early indicator of cardiac dysfunction in 
postmenopausal women (8, 20, 79, 107). 
In this study, intergroup differences in mRNA levels of fetal genes show that only 
8 weeks of ovarian hormone loss caused changes in cardiac gene expression. 
Ovariectomized mice had greater mRNA levels of cardiac stretch hormones ANP and 
BNP compared to sham mice, suggesting that ovarian hormone loss is associated with 
changes indicative of increased cardiac stretch. Though we cannot confirm this with 
mechanical data on the degree of chamber stretch or wall strain or blood pressure in these 
animals, the data suggest that OVX was associated with altered natriuretic peptide 
maintenance of blood pressure homeostasis.  
In normal physiological conditions, cardiac expression of ANP and BNP 
functions to counterbalance the renin angiotensin aldosterone system (RAAS), primarily 
by activating guanylyl cyclase-A (GC-A), which promotes vasorelaxation, natriuresis, 
and diuresis when active (15, 21, 38, 52, 83). ANP and BNP also suppress the RAAS by 
reducing plasma renin activity and ANP is able to directly inhibit renin production in the 
kidneys, providing a direct hormonal link between the heart and renal system (15, 57, 
75). In pathological cases of hypertension and heart failure, this balance is lost and 
natriuretic peptide expression increases as RAAS activity escalates (15).  
This pathological failure of homeostasis may also be a product of postmenopausal 
ovarian hormone loss as an increasing amount of evidence suggests that estrogen is a 
critical regulator of the RAAS (119). Estrogen controls synthesis of angiotensinogen, an 
upstream precursor of AngI and AngII that is activated by renin (53). Studies have found 
that compared to E2-replete counterparts, E2 deficient rats as well as postmenopausal 
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women have higher levels of circulating plasma renin and have greater activity of 
angiotensinogen-converting enzyme (ACE), the enzyme that regulates AngII production. 
Additionally, E2-deficient hypertensive rats have greater levels of circulating AngII 
compared to E2-replete counterparts (27, 119). These studies show that estrogen 
regulates production of angiotensinogen and conversion to angiotensin II by regulating 
enzyme activity. As a result, estrogen is able to modulate RAAS activity and prevent 
homeostatic imbalance and pathological upregulation of natriuretic peptides in the heart.  
Our data suggests that ovarian hormone deficiency led to increased RAAS 
activity as cohort 1 OVX mice had 5.28-fold greater levels of cardiac AngII mRNA 
compared to SHAM mice and greater cardiac natriuretic peptide expression pattern in the 
hearts of ovariectomized mice.  Surprisingly, the negative effects of ovarian hormone loss 
on the heart occurred within only 8 weeks of ovariectomy.  Increased adiposity, 
expression of systemic inflammatory markers, and other the systemic changes associated 
with ovariectomy may also have increased cardiac strain and resulted in ANP and BNP 
upregulation (60). The degree of wall strain and the mechanics of cardiac chamber 
dilation in a model of ovarian hormone loss should be investigated to further understand 
the effects of postmenopausal physiology on cardiac pathology. 
 Our data revealed additional indicators that OVX animals experienced cardiac 
dysfunction compared with SHAM animals.  OVX mice expressed lower levels of 
cardiac contractile protein isoforms α-MHC and β-MHC compared to SHAM mice. 
Downregulation of α-MHC and greater prevalence of β-MHC is the disease-associated 
re-expression of a fetal pattern in mice hearts. Changes in myosin heavy chain expression 
have been established in models of acute stress or extreme cardiac dysfunction. Studies of 
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pressure/volume overload and spontaneous hypertension in rat models showed a 
significant transition in cardiac gene expression from predominantly α-MHC to the 
disease-associated β-MHC (42, 107). These models involved drastic perturbations to 
cardiac homeostasis; the myosin heavy chain expression pattern in cohort 1 
ovariectomized mice may have not been affected as severely after only 8 weeks of 
ovarian hormone loss; and therefore, only an upregulation of β-MHC was observed 
without a downregulation of α-MHC. Potentially, the upregulation of β-MHC precedes 
the downregulation of α-MHC during the earliest stages of cardiac dysfunction. 
 McMullen et al. reported that the calcium handler SERCA 2a mRNA expression 
was downregulated in a model of cardiac pressure overload indicating that calcium 
reuptake from the sarcoplasmic reticulum suffers in a model of cardiac dysfunction (71).  
Other animal models of induced hypertrophy have shown radical upregulation of 
SERCA-2a, suggesting that calcium handling exhibits a bimodal response to cardiac 
stress. Initial increases in SERCA-2a levels are hypothesized to be part of an energy-
conserving mechanism in environments of mild cardiac stress; though some studies have 
shown discrepancies in SERCA-2a regulation with mild hypertrophy (1). In cohort 1 of 
our study, there were no significant differences in SERCA-2a gene expression between 
OVX and SHAM mice indicating that calcium handling was not affected by 8 weeks of 
ovarian hormone loss. Future studies should examine whether contractile dysfunction and 
SERCA-2a upregulation is initiated in a model of ovarian hormone loss at later time 
points. 
The expression of muscle filament α-ska was significantly greater in OVX mice 
compared to sham, suggesting a transition from cardiac actin to the skeletal muscle 
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isoform. Skeletal actin is predominantly expressed during fetal heart growth periods, and 
the re-emergence of this expression pattern has been documented throughout the 
progression of cardiac hypertrophy and heart disease (5, 8, 42, 107). Upregulation of α-
ska may show an effect of short term ovarian hormone loss on heart muscle filament 
expression that resembles the stress-inducing effects of fetal growth and heart disease.  
5.2 Ovariectomy Activates Cardiac Fibrosis Associated Genes 
 Cardiac tissue fibrosis is associated with pathological remodeling of the 
myocardium in response to increased total peripheral resistance, cardiac hypertrophy, and 
acute cardiac injury such as a myocardial infarction (24, 96). These risk factors increase 
the volume load on the heart and in order to achieve the necessary contractile strength, 
cardiac myocytes begin to hypertrophy. The accompanied infiltration of inflammatory 
cells as well as the muscle growth increases intercellular space (124). Resident cells, 
predominantly cardiac fibroblasts (CFBs), upregulate protein expression of ECM fibers 
in order to maintain wall structure and proper contractility (24, 48). While the heart is 
able to compensate this way for some time, increased cardiac hypertrophy and fibrosis 
can lead to maladaptive chamber dilation and wall stiffening, eventually resulting in 
contractile dysfunction.  We aimed to explore if ovarian hormone loss and the associated 
systemic physiological changes induced cardiac fibrosis or initiated mRNA expression of 
profibrotic markers in the heart. Assessing transcription of profibrotic genes in 
ovariectomized mice could provide a strong link between the effects of ovarian hormone 
loss on heart tissue and the increased risk of heart disease after menopause. The majority 
of the literature has explored increases in ECM fiber deposition and myofibroblast (MFB) 
formation using models of acute cardiac injury or induced spontaneous hypertension, 
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showing that ovarian hormones such as estrogen can reduce pathological remodeling of 
the heart (23, 80, 81, 110). Our mouse model can help elucidate fibrosis-associated 
changes caused by ovarian hormone loss alone; without the effects of acute injuries, 
hypertension, or transgenically induced diseases. 
Analysis of gene expression data revealed that ECM fiber expression was affected 
by ovarian hormone loss. Cardiac expression of collagen 1 and collagen 3 was 2.16- and 
2.47-fold greater in ovariectomized mice compared to mice with sham surgery. Both 
collagen isoforms are present in the ECM of a healthy myocardium, but prolonged or 
drastic upregulation of collagen fibers is indicative of pathological fibrosis. An integral 
part of maladaptive fibrosis is the differentiation of CFB cells into the MFB phenotype 
and the initial stage of this differentiation process is characterized by the formation of an 
intercellular matrix that is dense with collagen. As differentiation progresses, these proto-
myofibroblasts also begin to secrete fibronectin and vimentin fibers that infiltrate the 
ECM (9, 10). Cardiac gene expression of fibronectin and vimentin was 3.23- and 2.16-
fold greater in OVX mice compared to mice that underwent sham surgery. This 
upregulation may be a product of preliminary shifts in the CFB phenotype resulting from 
ovarian hormone loss and associated systemic changes.  
The estrogen-controlled RAAS is part of a possible mechanism that provides a 
relationship between ovarian hormone loss and changes in ECM fiber gene expression; 
this pathway may also explain the effects of postmenopausal physiology on cardiac 
dysfunction in women (15, 119). Apart from balancing natriuretic peptide activity, AngII 
(circulating and local) is an upstream activator of TGFβ-1 in cardiac fibroblasts, which 
promotes fibrosis and CFB differentiation (87). Higher levels of cardiac AngII mRNA in 
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ovariectomized mice may have stimulated TGFβ-1 expression, which was 2.97-fold 
greater in OVX compared to SHAM. In pathological cardiac fibrosis, TGFβ-1 acts via a 
SMAD pathway to initiate CFB differentiation to an MFB cell type (58, 59, 62, 81). The 
activation of this pathway by RAAS hyperactivity in ovariectomized mice could provide 
a mechanism for the ECM fiber expression results found in cohort 1. 
There were no intergroup significant differences in gene expression of endothelin-
1 and α-smooth muscle actin, two markers that characterize MFB differentiation and 
cardiac tissue fibrosis. The hearts of the ovariectomized mice may be expressing early 
signs of cardiac dysfunction that precede myocardial remodeling. The mice were 
sacrificed 8 weeks post surgery and this early time point highlights the influential role of 
ovarian hormones on cardioprotection. More importantly, the reduction in circulating 
ovarian hormones may impact cardiac function in women at early stages post menopause. 
Differences in expression levels of genes associated with fibrosis and ECM fiber 
deposition provide preliminary information regarding the effects of ovarian hormone loss 
on cardiac health. Future studies with analysis of protein expression and ECM thickness 
can provide more information regarding physical changes in the myocardium. 
5.3 Exercise inhibits a pathological gene expression pattern with ovariectomy 
 Physical activity has been shown to improve cardiac function, diminish 
pathological myocardial remodeling, and lower the risk for heart disease (39). Using 
cohort 2, we investigated the effects of physical activity on the pathological cardiac 
expression pattern. With swim training, McMullen et al. found that mouse cardiac gene 
expression of ANP and BNP were lower compared with sedentary animals, exhibiting a 
healthy adult pattern, thus demonstrating the potential benefits of exercise on lowering 
45 
 
markers of cardiac dysfunction (71). In cohort 2, we found no effect of group or 
condition on cardiac ANP and BNP gene expression; despite high standard error, ANP 
expression is 2.08-fold greater in hearts of OVX SED mice compared to SHAM SED. 
Between the two natriuretic hormones, ANP plays a greater role in RAAS regulation than 
BNP. ANP directly inhibits renin secretion from the juxtaglomerular cells of the kidneys 
and functions to maintain natriuresis and dieresis by inhibiting RAAS hyperactivity (15). 
Research shows that exercise improves renal function and is effectively able to prevent, 
reduce, and delay chronic kidney disease. ANP expression may have been downregulated 
as exercise was able to regulate RAAS activity. 
On the other hand, in a study investigating fetal gene reactivation in 8 week old 
treadmill trained rats, Kemi et al. found that after 6 weeks, cardiac expression of ANP 
was not different between trained and sedentary groups (51). In this study, animals were 
not diseased. The re-expression of fetal genes has been established as a sign of 
pathological changes in cardiac tissue, while exercise associated physiological changes in 
cardiac expression follow a distinctly separate pathway (42, 51, 107).   
 There was a significant group by condition interaction in expression of α-MHC 
and β-MHC though contrary to cohort 2 results, cohort 1 OVX SED mice expressed 
greater levels of cardiac α-MHC and β-MHC compared to SHAM SED. The increase in 
expression of β-MHC with ovariectomy may illustrate the pathological effects of ovarian 
hormone loss on myosin heavy chain isoform expression in cardiac tissue. With exercise, 
ovariectomized mice showed significantly lower mRNA expression of β-MHC compared 
to sedentary counterparts, suggesting a cardioprotective role of exercise that influences 
myosin heavy chain isoform expression in the heart. The greater β-MHC expression in 
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the SHAM EX group compared to SHAM SED may be a result of low sample size and 
high variability between individual mice. These limitations may also explain the 
expression pattern of α-ska, which showed no significant difference with ovariectomy, 
unlike the results of cohort 1 samples. Gene expression of α-ska was not different 
between sedentary and exercise conditions, which mirrors findings by Kemi et al. 
wherein cardiac mRNA expression of α-ska showed no significant differences between 
sedentary and treadmill trained rats. 
 Calcium handling in the heart becomes compromised with cardiac injury and the 
associated pathological response. McMullen et al showed that SERCA 2a, a calcium 
handler in cardiac tissue, is downregulated in the disease model compared to sham 
surgery and that exercise showed mRNA expression similar to sham (5, 71). The fetal 
gene program and calcium handling in particular has not been characterized in a model of 
ovarian hormone loss. Cohort 2 showed greater SERCA 2a expression with ovariectomy 
and lower expression with exercise. The expression pattern found with cohort 2 may be a 
compensatory mechanism for the systemic stress associated with postmenopausal 
physiology.  
5.4 Exercise may play a role in limiting pathological remodeling of the myocardium 
 Exercise induced physiological cardiac hypertrophy and remodeling occurs 
through molecular pathways involving growth factors and other signaling molecules 
distinct from the inflammatory pathways activated in pathological myocardial fibrosis 
(51). This beneficial adaptation results from sustained exercise training, is associated 
with normal or improved heart function, and is a reversible process (5). We hypothesized 
that mice exposed to voluntary wheel running would express lower levels of cardiac 
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markers associated with fibrosis and genes coding for ECM proteins compared to the 
sedentary counterparts within OVX and SHAM groups. There was a significant group by 
condition interaction in cardiac gene expression of Angiotensin II and OVX EX mice 
hearts had 4.15-fold greater AngII expression compared to OVX SED and SHAM EX 
(p=0.001). Physical activity is associated with decreased plasma renin activity and 
lowered levels of circulating AngII in models of heart failure (126). Circulating 
angiotensin and activation of RAAS balances natriuretic peptide release from the heart to 
regulate blood pressure in normal physiology (89, 121). The AngII expression pattern in 
cohort 2 may differ from our initial hypothesis because of lower levels of ANP and BNP 
in the exercise conditions. ET-1 and Tgfβ-1, mediators of MFB formation, had similar 
expression patterns as α-sma, a characteristic marker of MFB cells, that may indicate 
activation of the differentiation pathway. There was a significant group effect (p=0.043) 
on ET-1 expression in cohort 2. There was a general pattern of ET-1, Tgfβ-1, and α-sma 
upregulation with ovariectomy and slight downregulation with exercise, indicating that 
exercise may influence the pathological differentiation of cardiac fibroblasts at early 
stages of ovarian hormone loss. 
 Exercise has been shown to reduce myocardial remodeling and fibrosis in 
ovariectomized spontaneously hypertensive rats. The expression pattern of ECM fibers in 
cohort 2 suggests that physical activity may also influence myocardial remodeling in an 
ovariectomized rodent model that is not subject to a major insult to the heart. Gene 
expression of ECM proteins followed a similar pattern of expression as ET-1, Tgfβ-1, 
and α-sma. There was a significant effect of condition on collagen 3 gene expression as 
this ECM fiber was downregulated in the exercise condition (p=0.048). Though collagen 
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1, vimentin, and fibronectin mRNA levels did not have significant effects of group or 
condition, the overall expression pattern of all four ECM fibers was consistent. Cardiac 
gene expression of Col1, Col3, Vim, and FN was greater in OVX SED mice compared to 
SHAM SED and was lower in the exercise conditions. This expression pattern suggests 
that the early pathological effects of ovarian hormone loss on cardiac gene expression can 
be attenuated for with exercise within a short period of time, highlighting the importance 
of physical activity in terms of disease prevention. 
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CHAPTER 6  
CONCLUSION 
The American Heart Association reports that as of 2013, 26% of women age 45 and 
older who have an initial recognized MI die within a year compared to 19% of men, 
mainly because women are more likely to suffer a heart attack later in life compared to 
men (28). This disparity between males and females illustrates the cardioprotective role 
of ovarian hormones and the importance of establishing the effects of menopause. We 
hypothesized that the hearts of ovariectomized mice would upregulate gene expression of 
markers of cardiac dysfunction and pathological fibrosis and that exercise would be able 
to lower the expression of these markers. Based on our results we found that OVX hearts 
did manifest early signs of cardiac dysfunction and expressed greater mRNA levels of 
profibrotic markers.  
As of 2015, approximately 20% of the United States population is between 50-64 
years of age as the country undergoes a demographic transition to an aging society. 
Seventy percent of this population enters their 60s previously diagnosed with at least one 
chronic condition (28). As a result, the disease burden of the aging population and 
associated healthcare costs are due to increase over the next few years and in order to 
diminish this amount of waste and improve quality of life for a large portion of the 
population, effective early interventions need to be assessed and established. Physical 
activity is not only associated with improved cardiac function, but is able to diminish 
insult-induced cardiac dysfunction and fibrosis in animal models of ovarian hormone 
loss. Despite limitations, cohort 2 data supported the finding that ovariectomy increased 
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expression of cardiac dysfunction markers and that exercise was able to attenuate for 
some of these gene expression differences. 
 The mice in this study were sacrificed 8 weeks post surgery, at a young adult age 
(16 weeks old), which shows that even a limited period of ovarian hormone loss affected 
cardiac expression pattern and activated a fetal expression program, indicating heart 
disease pathology. Cardiac fibrosis and myocardial remodeling has been well established 
in models of acute cardiac injury or advanced stages of hypertension and heart disease 
(33, 96, 105). Our novel findings showed that mRNA levels of profibrotic markers and 
ECM fibers were upregulated in ovariectomized mice compared to sham. The effect of 
short term ovarian hormone loss on cardiac gene expression highlights the relationship 
between postmenopausal physiology and the increased risk for heart disease and 
necessitates the early timing of healthy preventative measures such as exercise. The CDC 
has reported that 1 in 3 female deaths is caused by heart disease and as this risk increases 
drastically after menopause, it is important to understand the immediate effects of ovarian 
hormone loss when determining treatment options.  
6.1 Strengths and Limitations 
 Most studies assessing expression patterns of fetal genes and cardiac fibrosis use 
models of acute or direct injury to the heart. Strengths of this study include the use of 
ovariectomy to replicate post menopausal physiology in order to investigate changes in 
expression of cardiac dysfunction markers due to the systemic changes associated with 
ovarian hormone loss. More importantly, this model was able to assess pathological 
effects of ovarian hormone loss on the heart at early time points, highlighting the degree 
of cardioprotection of ovarian hormones as well as the need for early intervention 
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methods to reduce the risk of heart disease in postmenopausal women. By investigating 
differences in gene expression, we were able to observe early changes in the heart caused 
by postmenopausal physiology.  
This study is not without limitations. Cohort 2 consisted of a limited number of 
animals, with five mice in each of the sedentary conditions (OVX and SHAM) and only 
four mice in each of the exercise conditions. The low sample size as well as other 
methodological differences between cohorts likely resulted in high individual variability 
and as a result some of the OVX versus SHAM comparisons in cohort 2 contradict 
findings with cohort 1. Primarily, cohort 1 animals were housed in groups together while 
cohort 2 animals were housed individually. Studies have shown that rodents prefer a 
group living dynamic and exhibit increased heart rate when housed individually (2, 101). 
Additionally food consumption was monitored in cohort 2 and animals may have had 
more human contact as food was removed for weighing daily.  
6.2 Future Directions 
Future research should use Western Blot or immunohistochemistry to investigate 
ECM protein expression as well as the differences in cardiac fibrosis in the hearts of 
ovariectomized mice compared to sham. Mouse echocardiography can also be utilized in 
order to determine the timing of symptoms indicating cardiac dysfunction in models of 
ovarian hormone loss. Establishing early effects of ovarian hormone loss on cardiac 
dysfunction markers can help develop possible preventative interventions, such as 
exercise, to reduce the risk of heart disease that is correlated with ovarian hormone loss. 
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APPENDIX 
RUNNING DATA 
Wheel running had been recorded for the cohort 2 subgroups in the EX condition; 
however the recorded data was lost and unable to be recovered during the original study. 
Running data below was collected from a study with a similar animal protocol at 
University of Maryland with previously published results (118). This study was 
conducted on C57/BL6 mice that were divided into sedentary and exercise cohorts. At 8-
weeks old, eleven mice were divided into two groups: a sham surgery group (SHAM, 
n=5) and a bilaterally ovariectomized (OVX, n=6). For 8 weeks, all mice were housed in 
individual cages that contained a voluntary wheel for exercise. Wheel revolutions were 
recorded by a computer attached to a photocell on each wheel. Data was populated 
through customized software (Lafayette Instruments, Lafayette, IN). 
All mice were given ad libitum access to water and standard rodent chow (Purina 
Laboratory Rodent Diet 5001:23% protein, 4.5%fat, 6% fiber) and were housed in a 
temperature controlled room on a 12h light/dark cycle.  Mice were removed from the 
wheel cages 24 hours prior to sacrifice and food was removed from all groups at this time 
as well. Tissues were harvested, snap frozen in liquid nitrogen, and stored at -80°C until 
processing.  The study was approved by the University of Maryland institutional Animal 
Care & Use Committee (IACUC). 
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Recorded running data for two groups; * indicates significant difference 
from sham surgery group (p<0.05). 
* 
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